CEO and Founder | Prof. Dr. H. H. Fiebig, MD, PhD

Prof. Dr. Heinz-Herbert Fiebig, is the founder and Chief Executive Officer of 4HF Biotec. He is retired Professor of Medical Oncology and Hematology at the University of Freiburg. In this function he conducted numerous Phase I and II clinical studies. His main research areas and expertise are discovery and preclinical evaluation of novel anticancer agents. He founded Oncotest GmbH in 1993, a preclinical CRO well known for its unique collection of patient derived tumor models and combined in-vitro and in-vivo testing procedures. With his team he investigated numerous targeted and cytotoxic anticancer drugs for pharmaceutical companies as well as in academic collaborations. Oncotest GmbH was acquired by Charles River Laboratories in Nov. 2015 when Prof. Fiebig decided to use his experience in anticancer drug discovery to start a new venture and he founded 4HF Biotec GmbH.

Prof. Fiebig is the author of more than 350 scientific publications. He was awarded the Czerny price of the German Society for Hematology and Oncology and the price of the German Ministry of Health for reducing animal experiments in cancer research.